Altered levels of acid, basic, and neutral peptidase activity and expression in human clear cell renal cell carcinoma

American Journal of Physiology - Renal Physiology

Volumn 292, Issue 2, 2007, Pages

  Varona, Adolfo ^a   Blanco, Lorena ^a   López, José I ^a   Gil, Javier ^a   Agirregoitia, Ekaitz ^a   Irazusta, Jon ^a   Larrinaga, Gorka ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Angiotensin II; Intracrine peptide signaling; Peptide hormones; Peptide metabolism; Renal tumor cell biology

Indexed keywords

5 OXOPROLYL PEPTIDASE; AMINOPEPTIDASE; AMINOPEPTIDASE B; ASPARTYL AMINOPEPTIDASE; GLUTAMYL AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; PEPTIDASE; PUROMYCIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; KIDNEY; KIDNEY CARCINOMA; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 33846864246     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00148.2006     Document Type: Article

References (45)

1. Ahmad S, Ward PE. Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins. J Pharmacol Exp Ther 252: 643-650, 1990.
2. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 120: 5-13, 2004.
3. Bannasch P, Zerban H. Animal models and renal carcinogenesis. In: Tumors and Tumor-Like Conditions of the Kidneys and Ureters, edited by Eble JN. New York: Churchill-Livingstone, 1990.
4. Bhagwat SV, Petrovic N, Okamoto Y, Shapiro LH. The angiogenic regulator CD13/APN is a transcriptional target of Ras signalling pathways in endothelial morphogenesis. Blood 101: 1818-1826, 2003.
5. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
6. Cadel S, Piesse C, Gouzy-Darmon C, Cohen P, Foulon T. Arginyl aminopeptidase. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum, 2004, p. 113-126.
7. Cesari M, Rossi GP, Pessina AC. Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. J Hypertens 20: 793-799, 2002.
8. Constam DB, Tobler AR, Rensing-Ehl A, Kemler I, Hersh LB, Fontana A. Puromycin-sensitive aminopeptidase: sequence analysis, expression and functional characterization. J Biol Chem 270: 26931-26939, 1995.
9. De Gasparo M, Bottari S, Levens NR. Characteristics of angiotensin II receptors and their role in cell and organ physiology. In: Hypertension; Pathophysiology, Diagnosis and Management, edited by Laragh JH and BM Brenner. New York: Raven, 1995, p. 1695-1710.
10. Furhman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
11. Göhring B, Holzhausen HJ, Meye A, Heynemann H, Rebmann U, Langner J, Riemann D. Endopeptidase 24.11/CD10 is down-regulated in renal cell cancer. Int J Mol Med 2: 409-414, 1998.
12. Grujic M, Renko M. Aminopeptidase inhibitors bestatin and actinonin inhibit cell proliferation of myeloma cells predominantly by intracellular interactions. Cancer Lett 182: 113-119, 2002.
13. Hallberg M, Le Grevès P, Nyberg F. Neuropeptide processing. In: Proteases in the Brain, edited by Lendeckel U and Hooper NM. New York: Springer Science Business Media, 2005, p. 203-234.
14. Ishii K, Usui S, Yamamoto H, Sugimura Y, Tatematsu M, Hirano K. Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J Biochem (Tokyo) 129: 253-258, 2001.
15. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91: 2268-2274, 1993.
16. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics 2005. CA Cancer J Clin 55: 10-30, 2005.
17. Kakinuma Y, Hama H, Sugiyama F, Goto K, Murakami K, Fukamizu A. Antiapoptotic action of angiotensin fragments to neuronal cells from angiotensinogen knockout mice. Neurosci Lett 232: 167-170, 1997.
18. Kehlen A, Göhring B, Langner J, Riemann D. Regulation of the expression of aminopeptidase A, aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 in renal carcinoma cells and renal tubular epithelial cells by cytokines and cAMP-increasing mediators. Clin Exp Immunol 111: 435-441, 1998.
19. Larrinaga G, Callado LF, Agirregoitia N, Varona A, Gil J. Subcellular distribution of membrane-bound aminopeptidases in the human and rat brain. Neurosci Lett 383: 136-140, 2005.
20. Mantle D, Lauffart B, McDermott J, Gibson A. Characterization of aminopeptidases in human kidney soluble fraction. Clin Chim Acta 187: 105-113, 1990.
21. Mantle D. Comparison of soluble aminopeptidases in human cerebral cortex, skeletal muscle and kidney tissues. Clin Chim Acta 207: 107-118, 1992.
22. Marinho CE, Olivo Rdo A, Zambotti-Villela L, Ribeiro-de-Andrade TN, Fernandes CM, and Silveira PF. Renal and macrophage aminopeptidase activities in cyclosporin-treated mice. Int Immunol 6: 415-425, 2006.
23. Martínez JM, Prieto I, Ramírez MJ, Cueva C, Alba F, Ramírez M. Aminopeptidase activities in Breast Cancer tissue. Clin Chem 45: 1797-1802, 1999.
24. Mentlein R, Roos T. Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides 17: 709-720, 1996.
25. Murphy WM, Grignon DJ, Perlman EJ. Tumors of the kidney, bladder, and related urinary structures. In: AFIP Atlas of Tumor Pathology 4th Series, Fascicle 1. Washington, DC: American Registry of Pathology, 2004, p. 101-240.
26. Nanus DM, Bogenrieder T, Papandreou CN, Finstad CL, Lee A, Vlamis V, Motzer RJ, Bander NH, Albino AP, Reuter VE. Aminopeptidase A expression and enzymatic activity in primary human renal cancers. Int J Oncol 13: 261-267, 1998.
27. Nanus DM, Engelstein D, Gastl GA, Gluck L, Vidal MJ, Morrison M, Finstad CL, Bander NH, Albino AP. Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proc Natl Acad Sci USA 90: 7069-7073, 1993.
28. Olivo R do A, Teixeira C de F, Silveira PF. Representative aminopeptidases and prolyl endopeptidase from murine macrophages: comparative activity levels in resident and elicited cells. Biochem Pharmacol 69: 1441-1450, 2005.
29. Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. Amino-peptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res 60: 722-727, 2000.
30. Petrov VV, Fagard RH, Lijnen PJ. Arginine-aminopeptidase in rat cardiac fibroblastic cells participates in angiotensin peptide turnover. Cardiovasc Res 61: 724-735, 2004.
31. Petrovic N, Schacke W, Shapiro LH. CD13/aminopeptidase N in tumor growth and angiogenesis. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum, 2004, p. 179-200.
32. Re RN. Implications of intracrine hormone action for physiology and medicine. Am J Physiol Heart Circ Physiol 284: H751-H757, 2003.
33. Rosenzwajg M, Tailleux L, Gluckman JC. CD13/N-aminopeptidase is involved in the development of dendritic cells and macrophages from cord blood CD34(+) cells. Blood 95: 453-460, 2000.
34. Saiki I, Fujii H, Yoneda J, Abe F, Nakajima M, Tsuruo T, Azuma I. Role of aminopeptidase N (CD13) in tumor-cell invasion and extracellular matrix degradation. Int J Cancer 54: 137-143, 1993.
35. Saiki I, Murata J, Watanabe K, Fujii H, Abe F, Azuma I. Inhibition of tumor cell invasion by ubenimex (bestatin) in vitro. Jpn J Cancer Res 80: 873-878, 1989.
36. Scornik OA, Botbol V. Effects on mammals of the aminopeptidase inhibitor bestatine. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum, 2004, p. 127-143.
37. Sekine K, Fujii H, Abe F, Nishikawa K. Augmentation of dead ligandinduced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. Int J Cancer 94: 485-491, 2001.
38. Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia 13: 729-734, 1999.
39. 1] angiotensin I by a novel aminopeptidase in the rat hypothalamus. Biochem Pharmacol 48: 1043-1046, 1994.
40. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours (6th ed.). New York: Wiley-Liss, 2002.
41. Stavropoulou V, Xie J, Henriksson M, Tomkinson B, Imreh S, Masucci MG. Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res 65: 1361-1368, 2005.
42. Tanioka T, Hattori A, Masuda S, Nomura Y, Nakayama H, Mizutani S, Tsujimoto M. Human leukocyte-derived arginine aminopeptidase. The third member of the oxytocinase subfamily of aminopeptidases. J Biol Chem 278: 32275-32283, 2003.
43. Thompson MW, Hersh LB. The puromycin-sensitive aminopeptidase. Role in neurological, reproductive, inmunological and proliferative disorders. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum 2004, p. 1-15.
44. Vetro JA, Dummitt B, Chang YH. Methionine-aminopeptidase: emerging role in angiogenesis. In: Aminopeptidases in Biology and Disease, edited by Hooper NM and Lendeckel U. New York: Kluwer Academic/Plenum, 2004, p. 17-44.
45. Wilk S, Wilk E, Magnusson RP. Purification, characterization and cloning of a cytosolic aspartyl aminopeptidase. J Biol Chem 273: 15961-15970, 1998.